Company Overview of Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. develops therapies for the treatment of dyslipidemia and cardiovascular diseases. Its products include Epanova, an Omega 3 fatty acid that has completed Phase III clinical studies to treat patients with triglycerides. The company has a license agreement with Chrysalis Pharma AG to develop and commercialize Epanova; and an agreement with BioVectra Inc. for the manufacture of the active pharmaceutical ingredient for Epanova. Omthera Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Princeton, New Jersey. As of July 18, 2013, Omthera Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca LP.
707 State Road
Princeton, NJ 08540
Founded in 2008
Key Executives for Omthera Pharmaceuticals, Inc.
Co-Founder and Chief Medical Officer
Chief Financial Officer and Vice President of Finance
Vice President of CMC/Manufacturing
Compensation as of Fiscal Year 2015.
Omthera Pharmaceuticals, Inc. Key Developments
Ligand Pharmaceuticals Inc. Inks Research and Licensing Pact with Omthera Pharmaceuticals, Inc
May 20 14
Ligand Pharmaceuticals Inc. announced that it has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, Inc. for the development of products to treat dyslipidemia, including hypertriglyceridemia. The research collaboration will target the development of novel products that utilize the proprietary Ligand-developed LTP Technology to improve lipid-lowering activity of certain omega-3 fatty acids. Under the terms of the agreement, Ligand will be eligible to receive payments of up to $44.5 million upon the achievement of specific milestones, as well as tiered royalties ranging from mid to high single digits of net sales. Omthera is solely responsible for all research and clinical development costs as well as commercialization of any product(s) derived from this collaboration.
Omthera Enters into Research and Licensing Agreement with Ligand Pharmaceuticals
May 15 14
Omthera (part of AstraZeneca, UK) and Ligand Pharmaceuticals have entered into a licensing agreement and research collaboration focused on the development of novel dyslipidaemia treatments utilising Ligand's LTP TECHNOLOGY to improve lipid-lowering activity of certain omega-3 fatty acids. As per the agreement, Omthera will take on the responsibility for the search and development costs. It would additionally be responsible for
the commercialising of any resulting products. In turn, Ligand will be liable to milestone payments of up to USD 44.5 million and tiered royalties on net sales of mid-to-high single digits.
Amarin Pharmaceuticals Ireland Limited Files Complaint Against Omthera Pharmaceuticals, Inc. and Astrazeneca Pharmaceuticals LP
Mar 4 14
Amarin Pharmaceuticals Ireland Limited announced that on March 4, 2014, the company, filed a complaint in the United States District Court for the District of Delaware against Omthera Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. The suit seeks injunctive relief and monetary damages for infringement of Amarin's U.S. Patent No. 8,663,662, which was issued by the United States Patent and Trademark Office. The complaint alleges infringement of the Patent arising from the expected launch of Epanova in the United States. The Patent covers methods of lowering triglycerides by administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than about 30% DHA. Amarin intends to pursue this litigation vigorously and aggressively protect its intellectual property rights.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|